Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways
Current Approach Of Phase III Studies ‘Is No Longer Justified In Many Cases’
• By David Wallace
Sandoz’s Pierre Bourdage sets out the case for tailored biosimilar development • Source: Sandoz 
